ImmunoGen Announces Webcast of Presentation at Upcoming Jefferies Virtual Healthcare Conference

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Mark Enyedy, President and CEO, and Anna Berkenblit, Chief Medical Officer, will participate in a fireside chat at the upcoming Jefferies Virtual Healthcare Conference. The presentation is scheduled for June 3, 2020 at 9:30am ET.

A webcast of the presentation will be accessible through the Investors and Media section of the Company's website on www.immunogen.com. Following the live webcast, a replay will be available at the same location.

ABOUT IMMUNOGEN ImmunoGen is developing the next generation of antibody-drug conjugates to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to “target a better now.”

Learn more about who we are, what we do, and how we do it at www.immunogen.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200520005760/en/

INVESTOR RELATIONS AND MEDIA ImmunoGen Courtney O’Konek 781-895-0600 [e-mail]

OR

FTI Consulting Robert Stanislaro 212-850-5657 [e-mail]